VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Immune escape is a prerequisite for tumor development. To avoid the immune system, tumors develop different mechanisms, including T cell exhaustion, which is characterized by expression of immune inhibitory receptors, such as PD-1, CTLA-4, Tim-3, and a progressive loss of function. The recent development of therapies targeting PD-1 and CTLA-4 have raised great interest since they induced long-lasting objective responses in patients suffering from advanced metastatic tumors. However, the regulation of PD-1 expression, and thereby of exhaustion, is unclear. VEGF-A, a proangiogenic molecule produced by the tumors, plays a key role in the development of an immunosuppressive microenvironment. We report in the present work that VEGF-A produced in the tumor microenvironment enhances expression of PD-1 and other inhibitory checkpoints involved in CD8+ T cell exhaustion, which could be reverted by anti-angiogenic agents targeting VEGF-A–VEGFR. In view of these results, association of anti-angiogenic molecules with immunomodulators of inhibitory checkpoints may be of particular interest in VEGF-A-producing tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Preclinical studies have demonstrated that VEGF blockade can reverse T cell failure and enhance the therapeutic effect of ICI [59,60].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [59]
In the citing paper
“expression of co-inhibitory receptors, including PD-1 by CD8 + CTLs”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Voron et al., 2015
In the citing paper
“First, increased VEGF directly inhibits CTL trafficking, proliferation, and effector function22”
From Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges (2018) · cites this paper as [22]
In the citing paper
“Secondly, VEGF could inhibit the maturation of DC, induce the exhaustion of T cells, promote the proliferation of Tregs, and increase the ratio of MDSCs [90–93].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [91]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“2015 Vol. 212 No. 2 139–148 www.jem.org/cgi/doi/10.1084/jem.20140559 139 Brief Definit ive Report One of the major processes involved in tumor appearance and growth is the capacity of tumor cells to develop escape mechanisms to the immune system (Schreiber et al., 2011).”
BackgroundInfluentialWherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 1×
“The mechanisms involved in PD-1 expression and exhaustion of tumor-infiltrating T cells are poorly understood, even though a link to antigen persistence has been suggested (Wherry, 2011).”
BackgroundSafety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., Daud, A., Hodi, F. S., Hwu, W.-J., Kefford, R., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,392
Molecular Signature of CD8+ T Cell Exhaustion during Chronic Viral Infection
Wherry, E. J., Ha, S.-J., Kaech, S. M., Haining, W. N., Sarkar, S., Kalia, V., Subramaniam, S., Blattman, J. N., Barber, D. L., & Ahmed, R. (2007) · Immunity · doi:10.1016/j.immuni.2007.09.006 · Cited by 2,103 · cited 1×
“In tumors or during chronic viral infections, PD-1 expression is maintained (Wherry et al., 2007).”
BackgroundTargeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · cited 6×
“Cell surface-staining was performed on tumor-infiltrating cells using antiCD8 (53–6.7; eBioscience), anti–PD-1 (J43; eBioscience), anti–CTLA-4 (UC10-4B9; BioLegend), anti–Lag-3 (C9B7W; BioLegend), anti–Tim-3 (RMT3-23; BioLegend), anti–mouse VEGF-R2 (89B3A5; BioLegend), and anti–mouse VEGF-R1 (141522; R&D Systems).”
BackgroundInfluentialBlackburn, S. D., Shin, H., Haining, W. N., Zou, T., Workman, C. J., Polley, A., Betts, M. R., Freeman, G. J., Vignali, D. A. A., & Wherry, E. J. (2009) · Nature Immunology · doi:10.1038/ni.1679 · Cited by 2,062 · cited 1×
“To determine whether VEGF-R1 or VEGF-R2 are involved in the T cells express these receptors the more they are dysfunctional (Blackburn et al., 2009).”
BackgroundGabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Cited by
Items 101–200 of 1,000
Role of mitochondrial alterations in human cancer progression and cancer immunity
Wang, S.-F., Tseng, L.-M., & Lee, H.-C. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00956-w · Cited by 192
Resistance mechanisms to immune checkpoint inhibitors: updated insights
Alsaafeen, B. H., Ali, B. R., & Elkord, E. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02212-7 · Cited by 191
“Moreover, role of VEGF in upregulating the expression of inhibitory immune checkpoint molecules, including PD-1, CTLA-4, LAG-3, TIM-3 and PD-L1, on tumor cells and intratumoral immune cells was documented [211–213].”
Immunomodulatory Activity of VEGF in Cancer
(2017) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2016.09.007 · Cited by 194
Self-citationBarriers to Radiation-Induced In Situ Tumor Vaccination
Wennerberg, E., Lhuillier, C., Vanpouille-Box, C., Pilones, K. A., García-Martínez, E., Rudqvist, N.-P., Formenti, S. C., & Demaria, S. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00229 · Cited by 194
“Treatment of CT26 tumor-bearing mice with VEGF-A antibody decreases the expression of these inhibitory receptors on CD8+ T cells isolated from the tumor and from hepatic metastases (69).”
BackgroundPark, Y.-J., Kuen, D.-S., & Chung, Y. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0130-1 · Cited by 194
Tumor angiogenesis revisited: Regulators and clinical implications
Ronca, R., Benkheil, M., Mitola, S., Struyf, S., & Liekens, S. (2017) · Medicinal Research Reviews · doi:10.1002/med.21452 · Cited by 193
Molecular Insight of Regorafenib Treatment for Colorectal Cancer
Arai, H., Battaglin, F., Wang, J., Lo, J. H., Soni, S., Zhang, W., & Lenz, H.-J. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2019.101912 · Cited by 191
New immunotherapies targeting the PD-1 pathway
Chinai, J. M., Janakiram, M., Chen, F., Chen, W., Kaplan, M., & Zang, X. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.06.005 · Cited by 189
Hendry, S. A., Farnsworth, R. H., Solomon, B., Achen, M. G., Stacker, S. A., & Fox, S. B. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00621 · Cited by 188
“VEGF-A also directly enhances the expression of PD-1, TIM-3, and CTLA-4 on intratumoral CD8+ T cells, contributing to T cell anergy (145).”
BackgroundChoi, Y., & Jung, K. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01114-w · Cited by 188
Wang, F., Jin, Y., Wang, M., Luo, H.-Y., Fang, W.-J., Wang, Y.-N., Chen, Y.-X., Huang, R.-J., Guan, W.-L., Li, J.-B., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02813-1 · Cited by 183
“Moreover, the addition of anti-angiogenic agents to ICIs can effectively inhibit the expression of multiple immune checkpoints induced by VEGF in tumors 14 .”
PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
Pesce, S., Greppi, M., Grossi, F., Del Zotto, G., Moretta, L., Sivori, S., Genova, C., & Marcenaro, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01242 · Cited by 187
“, HCMV) (62) and/or soluble factors released in the tumor microenvironment (including endogenous glucocorticoids) may be involved in PD-1 induction (67, 68) (Figure 1).”
BackgroundDirect and Indirect Modulation of T Cells by VEGF-A Counteracted by Anti-Angiogenic Treatment
Bourhis, M., Palle, J., Galy-Fauroux, I., & Terme, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.616837 · Cited by 184
“Moreover, the administration of anti-VEGF-A in tumor-bearingmice decreased PD-1 expression on intratumoral CD8 T-cells and limited the co-expression of inhibitory checkpoints associated with exhaustion (44).”
BackgroundInfluentialSelf-citationBastman, J. J., Serracino, H. S., Zhu, Y., Koenig, M. R., Mateescu, V., Sams, S. B., Davies, K. D., Raeburn, C. D., McIntyre, R. C., Haugen, B. R., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4227 · Cited by 181
“Furthermore, a recent study showed that VEGF-A and its receptors directly inhibit CD8 T cells through the up-regulation of PD-1 and other inhibitory molecules (67).”
The function and dysfunction of memory CD 8+ T cells in tumor immunity
Reading, J. L., Gálvez‐Cancino, F., Swanton, C., Lladser, A., Peggs, K. S., & Quezada, S. A. (2018) · Immunological Reviews · doi:10.1111/imr.12657 · Cited by 180
Hypoxia-induced epithelial to mesenchymal transition in cancer
Hapke, R. Y., & Haake, S. M. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.05.012 · Cited by 178
“VEGF suppresses T-cell activation through VEGF receptor-2 (VEGFR-2) signaling within the T-cell and increases PD-1 expression on CD8+ T-cells, while VEGFR inhibition reversed both[165,166].”
BackgroundMechanisms of immune escape in the cancer immune cycle
Tang, S., Ning, Q., Yang, L., Mo, Z., & Tang, S. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106700 · Cited by 178
Nagl, L., Horvath, L., Pircher, A., & Wolf, D. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00766 · Cited by 180
“The first aspect is that VEGFs are immunosuppressive, as they inhibit T cell infiltration and decrease maturation and function (antigen presentation) of DC, expand Treg and foster PD-1 expression (Ohm and Carbone, 2001; Voron et al., 2015).”
BackgroundGermline genetic contribution to the immune landscape of cancer
Sayaman, R. W., Saad, M., Thorsson, V., Hu, D., Hendrickx, W., Roelands, J., Porta-Pardo, E., Mokrab, Y., Farshidfar, F., Kirchhoff, T., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.01.011 · Cited by 179
Sheng, X., Yan, X., Chi, Z., Si, L., Cui, C., Tang, B., Li, S., Mao, L., Lian, B., Wang, X., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00210 · Cited by 175
“In addition to its role in vascular growth, VEGF has also emerged as an important immunosuppressive agent in the tumor microenvironment.(21,22) In vivo studies have shown that angiogenesis inhibition,(23) specifically simultaneous inhibition of the VEGF receptor (VEGFR) and PD-1 pathways in a mouse model, increased T-…”
BackgroundDeng, H., Kan, A., Lyu, N., Mu, L., Han, Y., Liu, L., Zhang, Y., Duan, Y., Liao, S., Li, S., et al. (2020) · Liver Cancer · doi:10.1159/000505695 · Cited by 173
Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer
Georganaki, M., van Hooren, L., & Dimberg, A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03081 · Cited by 172
Meder, L., Schuldt, P., Thelen, M., Schmitt, A., Dietlein, F., Klein, S., Borchmann, S., Wennhold, K., Vlasic, I., Oberbeck, S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2176 · Cited by 170
Wang, F., He, M.-M., Yao, Y.-C., Zhao, X., Wang, Z.-Q., Jin, Y., Luo, H.-Y., Li, J.-B., Wang, F.-H., Qiu, M.-Z., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100383 · Cited by 167
“Anti-angiogenic molecules, which target VEGF/VEGFR axis, can counteract the tumor-induced immunosuppression by reducing regulatory T cells and increasing CD8 T cell infiltration.(10,11) In addition, regorafenib reduced tumor-associated macrophages in tumor models by inhibiting other targets, including colony-stimulati…”
BackgroundStrategies to Improve the Antitumor Effect of Immunotherapy for Hepatocellular Carcinoma
Xing, R., Gao, J., Cui, Q., & Wang, Q. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.783236 · Cited by 167
“presentation by promoting differentiation and maturation of DCs, but also activate cytotoxic CD8 T cells (68, 69).”
Targeted modulation of immune cells and tissues using engineered biomaterials
Yousefpour, P., Ni, K., & Irvine, D. J. (2023) · Nature Reviews Bioengineering · doi:10.1038/s44222-022-00016-2 · Cited by 164
Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
Mushtaq, M. U., Papadas, A., Pagenkopf, A., Flietner, E., Morrow, Z., Chaudhary, S. G., & Asimakopoulos, F. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0376-0 · Cited by 165
Immune Landscape of Colorectal Cancer Tumor Microenvironment from Different Primary Tumor Location
Zhang, L., Zhao, Y., Dai, Y., Cheng, J.-N., Gong, Z., Feng, Y., Sun, C., Jia, Q., & Zhu, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01578 · Cited by 166
Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
Vaccine-based immunotherapeutic approaches to gliomas and beyond
Weller, M., Roth, P., Preusser, M., Wick, W., Reardon, D. A., Platten, M., & Sampson, J. H. (2017) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.64 · Cited by 162
Mougel, A., Terme, M., & Tanchot, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00467 · Cited by 161
Self-citationOvarian Cancer Immunotherapy: Turning up the Heat
Ghisoni, E., Imbimbo, M., Zimmermann, S., & Valabrega, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20122927 · Cited by 161
Drug Resistance in Colorectal Cancer: From Mechanism to Clinic
Wang, Q., Shen, X., Chen, G., & Du, J. (2022) · Cancers · doi:10.3390/cancers14122928 · Cited by 160
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy
Giannone, G., Ghisoni, E., Genta, S., Scotto, G., Tuninetti, V., Turinetto, M., & Valabrega, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124414 · Cited by 159
“Lastly, from a biohumoral point of view, the vascular endothelial growth factor (VEGF) both induces the growth of MDSCs and enhances their immune-modulatory activity [44,45].”
BackgroundPD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies
Lin, K. X., Istl, A. C., Quan, D., Skaro, A. I., Tang, E. S.-T., & Zheng, X. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03520-5 · Cited by 178
“VEGF also directly inhibits the differentiation of progenitor cells into conventional T cells, decreasing T cell proliferation and cytotoxicity and prompting PD-L1-driven T cell exhaustion [47, 48].”
BackgroundMechanisms of T-Cell Exhaustion in Pancreatic Cancer
Saka, D., Gökalp, M., Piyade, B., Cevik, N. C., Arik Sever, E., Unutmaz, D., Ceyhan, G. O., Demir, I. E., & Asimgil, H. (2020) · Cancers · doi:10.3390/cancers12082274 · Cited by 155
Glaviano, A., Lau, H., Carter, L. M., Lee, E. H. C., Lam, H. Y., Okina, E., Tan, D. J. J., Tan, W., Ang, H. L., Carbone, D., et al. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01634-6 · Cited by 182
Improving the Efficiency of Vγ9Vδ2 T-Cell Immunotherapy in Cancer
Hoeres, T., Smetak, M., Pretscher, D., & Wilhelm, M. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00800 · Cited by 154
“For example VEGF facilitates neo-angiogenesis and immunosuppressive effects (232, 233) but also promotes tissue trafficking of different leukocytes (234, 235).”
BackgroundTumor microenvironment for cancer stem cells
Kise, K., Kinugasa‐Katayama, Y., & Takakura, N. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.08.005 · Cited by 166
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
To, K. K. W., Fong, W., & Cho, W. C. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.635007 · Cited by 175
Rationally Combining Anti-VEGF Therapy with Checkpoint Inhibitors in Hepatocellular Carcinoma
Hato, T., Zhu, A. X., & Duda, D. G. (2016) · Immunotherapy · doi:10.2217/imt.15.126 · Cited by 161
Cousin, S., Cantarel, C., Guégan, J., Gomez‐Roca, C., Metges, J., Adenis, A., Pernot, S., Bellera, C. A., Kind, M., Auzanneau, C., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3416 · Cited by 160
“Furthermore, VEGF-A which is abundant in the tumor microenvironment of human tumors has been shown to upregulate the expression of PD-1 which play a crucial role in CD8+ T cell exhaustion [9].”
BackgroundSelf-citationHsu, C., Ou, D., Bai, L., Chen, C., Lin, L., Huang, S.-F. K., Cheng, A., Jeng, Y., & Hsu, C. (2021) · Liver Cancer · doi:10.1159/000515305 · Cited by 160
Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment
Wang, Q., & Wu, X. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.03.015 · Cited by 153
Liu, L., Bai, H., Wang, C., Seery, S., Wang, Z., Duan, J., Li, S., Xue, P., Wang, G., Sun, Y., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.03.016 · Cited by 149
Immunological off-target effects of imatinib
Zitvogel, L., Rusakiewicz, S., Routy, B., Ayyoub, M., & Kroemer, G. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.41 · Cited by 142
Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy
Kim, J.-H., Kim, B. S., & Lee, S. (2020) · Immune Network · doi:10.4110/in.2020.20.e4 · Cited by 157
“Furthermore, researchers have established that treatment of a humanized anti-VEGFR2 mAb, ramucirumab, led to a decrease in PD-1 expression in CD8+ T cells and a reduction in eTreg infiltration into the TME (49,119).”
BackgroundLasorsa, F. M., di Meo, N. A., Rutigliano, M., Milella, M., Ferro, M., Pandolfo, S. D., Crocetto, F., Tătaru, O. S., Autorino, R., Battaglia, M., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11041071 · Cited by 160
“In ccRCC, VHL loss results in an increased expression of VEGF, which has recently been associated with the upregulation of PD-1 and TIM-3 on CD8-T cells [81].”
BackgroundCombination Approaches with Immune-Checkpoint Blockade in Cancer Therapy
Swart, M., Verbrugge, I., & Beltman, J. B. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00233 · Cited by 139
Tumour microenvironment responsive nanoconstructs for cancer theranostic
Gulzar, A., Xu, J., Wang, C., He, F., Yang, D., Gai, S., Yang, P., Lin, J., Jin, D., & Xing, B. (2019) · Nano Today · doi:10.1016/j.nantod.2019.03.007 · Cited by 139
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
Rassy, E., Flippot, R., & Albiges, L. K. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920907504 · Cited by 142
Hossain, M. A., Liu, G., Dai, B., Si, Y., Yang, Q., Wazir, J., Birnbaumer, L., & Yang, Y. (2020) · Medicinal Research Reviews · doi:10.1002/med.21727 · Cited by 154
Direct and indirect regulation of the tumor immune microenvironment by VEGF
Zhang, Y., & Brekken, R. A. (2022) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ru0222-082r · Cited by 156
Advancements in combining targeted therapy and immunotherapy for colorectal cancer
Singh, M., Morris, V. K., Bandey, I. N., Hong, D. S., & Kopetz, S. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.05.001 · Cited by 155
NF-κB signaling pathway in tumor microenvironment
Cao, Y., Yi, Y., Han, C., & Shi, B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1476030 · Cited by 164
Xu, W., Hiếu, T., Malarkannan, S., & Wang, L. L. (2018) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.148 · Cited by 144
Immunotherapeutic interventions of Triple Negative Breast Cancer
Li, Z., Qiu, Y., Lu, W., Jiang, Y., & Wang, J. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1514-7 · Cited by 143
“VEGF-A produced in the TME enhances expression of PD-1 and other immune checkpoint molecules, and high levels of VEGF-A might be involved in resistance to PD-1 blockades, which could be reverted by targeting the VEGF-A/VEGFR pathway [90].”
BackgroundLong, Y., Tao, H., Karachi, A., Grippin, A., Jin, L., Chang, Y., Zhang, W., Dyson, K. A., Hou, A. Y., Meng, N., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1577 · Cited by 140
“Furthermore, we evaluated the previously published microarray analysis of chemona€ ve patients with GBM or patients who had failed bevacizumab treatment (22–24).”
BackgroundResultInfluentialCourau, T., Nehar-Belaid, D., Florez, L., Levacher, B., Vazquez, T., Brimaud, F., Bellier, B., & Klatzmann, D. (2016) · JCI Insight · doi:10.1172/jci.insight.85974 · Cited by 131
“VEGF can also induce Treg proliferation (25, 26) and inhibits the activity of Teffs in the tumor (27).”
BackgroundMethodResultThe therapeutic implications of immunosuppressive tumor aerobic glycolysis
Reinfeld, B. I., Rathmell, W. K., Kim, T. K., & Rathmell, J. C. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00727-3 · Cited by 149
Wang-Bishop, L., Kimmel, B. R., Ngwa, V. M., Madden, M. Z., Baljon, J. J., Florian, D. C., Hanna, A., Pastora, L. E., Sheehy, T. L., Kwiatkowski, A. J., et al. (2023) · Science Immunology · doi:10.1126/sciimmunol.add1153 · Cited by 126
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Buqué, A., Bloy, N., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Fridman, W. H., Fucikova, J., Galon, J., Marabelle, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008814 · Cited by 129
“(Hôpital Europ een Georges Pompidou; Paris, France) who showed that vascular endothelial growth factor A (VEGFA) promotes the expression of PD-1 and other molecules involved in immunological checkpoints, delineating a therapeutically relevant, immunosuppressive response to hypoxia that can be reverted by anti-angiogen…”
BackgroundNew agents on the horizon in gastric cancer
Lordick, F., Shitara, K., & Janjigian, Y. Y. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx051 · Cited by 131
“Prolonged exposure to VEGF-A was reported to induce the expression of inhibitory molecules and to exhaust CD8-positive T cells in a mouse model, indicating the possibility of the combined use of immune checkpoint inhibitors with VEGF inhibitors [43].”
BackgroundDarragh, L. B., Oweida, A. J., & Karam, S. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03154 · Cited by 137
“Induced by RT, VEGF-A can also increase inhibitory receptors on CD8+ T cells (e.g., Tim-3, CTLA-4, PD-1, Lag-3) (85) as well as PDL-1 expression on tumor cells and MDSCs (86), thereby promoting T cell exhaustion and inactivity (85).”
BackgroundPD‐1/PD‐L1‐dependent immune response in colorectal cancer
Payandeh, Z., Khalili, S., Somi, M. H., Mard‐Soltani, M., Baghbanzadeh, A., Hajiasgharzadeh, K., Samadi, N., & Baradaran, B. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29494 · Cited by 137
“A‐VEGFR and PD‐1/PD‐L1 pathway Enhance the efficacy of anti‐PD‐1/PD‐L1 therapy in colorectal cancer (Voron et al., 2015) Combination with PI3‐kinase γ (PI3Kγ) signaling in myeloid cells and macrophages Combination of PI3Kγ inhibitors and anti‐PD‐1/PD‐L1 to overcome resistance to anti‐PD‐1/PD‐L1…”
Capozzi, M., Divitiis, C. D., Ottaiano, A., von Arx, C., Scala, S., Tatangelo, F., Delrio, P., & Tafuto, S. (2019) · Cancer Management and Research · doi:10.2147/cmar.s188316 · Cited by 138
“In addition, regulatory T cells express VEGFR-2, and stimulation through VEGF-A is connected with PD-1 increase and inhibition of T cells.(30) A preclinical study in renal cell carcinoma (RCC) demonstrated that cellular immunotherapy in association with lenvatinib significantly increases survival in murine models;(31)…”
BackgroundQin, S., Ren, Z., Feng, Y.-H., Yau, T., Wang, B., Zhao, H., Bai, Y., Gu, S., Li, L., Hernandez, S., et al. (2021) · Liver Cancer · doi:10.1159/000513486 · Cited by 127
Antiangiogenic–immune-checkpoint inhibitor combinations: lessons from phase III clinical trials
Kuo, H., Khan, K. A., & Kerbel, R. S. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00886-y · Cited by 151
Mechanisms of resistance to immune checkpoint inhibitors
Nagasaki, J., Ishino, T., & Togashi, Y. (2022) · Cancer Science · doi:10.1111/cas.15497 · Cited by 138
Immune cell therapy for hepatocellular carcinoma
Mizukoshi, E., & Kaneko, S. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0742-5 · Cited by 131
“Because VEGF increases TAMs and Tregs and enhances the expression of immune checkpoint molecules including PD1 molecules of CD8positive T cells [119, 120], combination therapy of VEGF inhibitors and anti-PD-1 antibodies makes sense.”
BackgroundAnti-PD-1/PD-L1 therapy for infectious diseases: learning from the cancer paradigm
Rao, M., Valentini, D., Dodoo, E., Zumla, A. I., & Maeurer, M. J. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2017.01.028 · Cited by 131
Vascular Endothelial Growth Factor, a Key Modulator of the Anti-Tumor Immune Response
Geindreau, M., Ghiringhelli, F., & Bruchard, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094871 · Cited by 135
“In the TME, tumor cells produce VEGF-A, which is able to increase programmed cell death 1 (PD-1), cytotoxic T-lymphocyte associated protein 4 (CTLA-4), and T cell immunoglobulin and mucin-domain containing-3 (TIM-3) on the CD8+ T cell surface, inducing T cell exhaustion [72], participating in the establishment of an i…”
BackgroundInfluentialVascular Normalization: A New Window Opened for Cancer Therapies
Yang, T., Xiao, H., Liu, X., Wang, Z., Zhang, Q., Wei, N., & Guo, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.719836 · Cited by 141
Doleschel, D., Hoff, S., Koletnik, S., Rix, A., Zopf, D., Kiessling, F., & Lederle, W. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02043-0 · Cited by 114
“Nevertheless, REG, as a potent inhibitor of VEGFA-signaling, may further add to reactivation of T cells, not only by reducing Treg cells but also by preventing VEGFA-induced PD1 expression in cytotoxic T cells [43], although this contribution was not measurable in the context of total intratumoral IFNγ levels.”
BackgroundBarnestein, R., Galland, L., Kalfeist, L., Ghiringhelli, F., Ladoire, S., & Limagne, E. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2120676 · Cited by 124
A CRISPR-Cas9 delivery system for in vivo screening of genes in the immune system
LaFleur, M. W., Nguyen, T. H., Coxe, M. A., Yates, K. B., Trombley, J. D., Weiss, S. A., Brown, F. D., Gillis, J. E., Coxe, D. J., Doench, J. G., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09656-2 · Cited by 116
The Research Progress of Antiangiogenic Therapy, Immune Therapy and Tumor Microenvironment
Hu, H., Chen, Y., Tan, S., Wu, S., Huang, Y., Fu, S., Luo, F., & He, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.802846 · Cited by 117
“Similarly, sunitinib inhibited the expansion of Tregs and MDSCs in patients with renal cell carcinoma (30, 63, 65).”
BackgroundTamura, R., Tanaka, T., Miyake, K., Yoshida, K., & Sasaki, H. (2017) · Brain Tumor Pathology · doi:10.1007/s10014-017-0284-x · Cited by 125
“Importantly, the combination of anti-PD-1 antibodies with VEGF blockade induced a strong and synergistic antitumor effect in tumors producing high levels of VEGF by suppressing Tregs and improving the migratory activity of cytotoxic T lymphocytes [46].”
BackgroundPernot, S., Terme, M., Radosevic‐Robin, N., Castan, F., Badoual, C., Marcheteau, E., Penault-Llorca, F. M., Bouché, O., Bennouna, J., François, É., et al. (2019) · Gastric Cancer · doi:10.1007/s10120-019-00983-3 · Cited by 123
Self-citationERS/ESTS/EACTS/ESTRO guidelines for the management of malignant pleural mesothelioma
Opitz, I., Scherpereel, A., Berghmans, T., Psallidas, I., Glatzer, M., Comas, D. R., Astoul, P. J., Bölükbas, S., Boyd, J., Coolen, J., et al. (2020) · European Journal of Cardio-Thoracic Surgery · doi:10.1093/ejcts/ezaa158 · Cited by 120
Gunda, V., Gigliotti, B., Ashry, T., Ndishabandi, D., McCarthy, M., Zhou, Z., Amin, S., Lee, K. E., Stork, T., Wirth, L., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32041 · Cited by 111
“Crosstalk between these complex microenvironmental pathways has been increasingly recognized; common driver alterations in the MAPK and PI3K pathways have been shown to increase programs of angiogenesis and cell proliferation/ survival, and increased VEGF secretion by both thyroid cancer cells and tumor-infiltrating m…”
BackgroundSudmeier, L. J., Hoang, K. B., Nduom, E. K.-E., Wieland, A., Neill, S. G., Schniederjan, M., Ramalingam, S. S., Olson, J. J., Ahmed, R., & Hudson, W. H. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100620 · Cited by 123
“We show that VEGF expression, for example, is enriched in the tumor parenchyma compared with the stroma; VEGF signaling has been found to promote PD-1, CTLA-4, TIM-3, and TOX expression on CD8 T cells.(53) This is consistent with the higher expression of these molecules that we observed on terminally differentiated CD…”
BackgroundMeyo, M. T., Jouinot, A., Leprieur, E. G., Fabre, E., Wislez, M., Alifano, M., Leroy, K., Boudou, P., Tlemsani, C., Khoudour, N., et al. (2020) · Cancers · doi:10.3390/cancers12020473 · Cited by 119
“Proangiogenic cytokine VEGFA is known to have an immunosuppressive function in vitro, and induces an increase of PD-1 expression on CD8+ T lymphocytes [20,21].”
BackgroundCombining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
Ciciola, P., Cascetta, P., Bianco, C., Formisano, L., & Bianco, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030675 · Cited by 121
“Moreover, VEGF binding to VEGFR2 on the surface of effector T cells has been shown to directly suppress their proliferation and cytotoxic function by the upregulation of the expression of PD-1 on CD8+ T lymphocytes [61].”
BackgroundGoedegebuure, R. S. A., de Klerk, L. K., Bass, A. J., Derks, S., & Thijssen, V. L. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03107 · Cited by 123
Di Tacchio, M., Macas, J., Weissenberger, J., Sommer, K., Bähr, O., Steinbach, J. P., Senft, C., Seifert, V., Glas, M., Herrlinger, U., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0865 · Cited by 104
“Indeed, VEGF has been demonstrated to contribute to T-cell exhaustion by the upregulation of immune checkpoints, including PD-1 (34).”
BackgroundLiu, Z., Zhang, Y., Shi, C., Zhou, X., Xu, K., Jiao, D., Sun, Z., & Han, X. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02697-y · Cited by 137
CD8+ T-cell exhaustion in cancer: mechanisms and new area for cancer immunotherapy
He, Q., Xu, Y., Li, J., Huang, Z., Li, X., & Wang, X. (2018) · Briefings in Functional Genomics · doi:10.1093/bfgp/ely006 · Cited by 121
Targeting angiogenesis for liver cancer: Past, present, and future
Zhu, X., Tang, Z., & Sun, H. (2020) · Genes & Diseases · doi:10.1016/j.gendis.2020.03.010 · Cited by 109
“Intratumoral VEGF overexpression exerts an immunosuppression microenvironment in tumors by accumulation of regulatory T cells, myeloid-derived suppressor cells, immunosuppressive cytokines, inhibiting DC maturation and production of IDO,(60,61) inhibiting T cell infiltration,(62) and upregulating the expression of imm…”
BackgroundSaeed, A., Park, R., & Sun, W. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01034-0 · Cited by 109
“Furthermore, increased VEGF levels leads to inhibition of cytotoxic T cell trafficking, proliferation, and effector function [9, 38, 39].”
BackgroundJurj, A. M., Ionescu, C., Berindan‐Neagoe, I., & Braicu, C. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02484-1 · Cited by 116
“Therefore, the elasticity property of the ECM modulates cell proliferation and angiogenesis by controlling the level of transcription factor that regulates the expression of VEGFR2 [248].”
BackgroundThe network of immunosuppressive pathways in glioblastoma
Mangani, D., Weller, M., & Roth, P. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.12.011 · Cited by 111
Anti-VEGF Treatment Enhances CD8+ T-cell Antitumor Activity by Amplifying Hypoxia
de Almeida, P. E., Mak, J., Hernandez, G., Jesudason, R., Hérault, A., Javinal, V., Borneo, J., Kim, J. M., & Walsh, K. B. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0360 · Cited by 113
“In preclinical tumor models, the combination of antiangiogenic agents with immunotherapy, such as anti–PD-1/PD-L1, have been effective (5, 53, 54, 63).”
BackgroundResultVito, C. D., Mikulak, J., Zaghi, E., Pesce, S., Marcenaro, E., & Mavilio, D. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.03.004 · Cited by 119
Ren, S., Xiong, X., You, H., Shen, J., & Zhou, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.689132 · Cited by 113
“Anlotinib is another small molecular inhibitor targeting multiple receptor tyrosine kinases (RTKs), including VEGFR2 and VEGFR3.”
BackgroundInfluentialImmunotherapy in Ovarian Cancer: Thinking Beyond PD-1/PD-L1
Chardin, L., & Leary, A. F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.795547 · Cited by 110
“Tregs constitutively express the co-inhibitory molecule, CTLA-4 which inhibits antigen presentation by binding on CD80 and CD86, co-stimulatory molecules expresses on DC. Tregs also inhibit CD8+ LT activation via IL-2 consumption which is necessary to T-cells activation.”
BackgroundInfluentialCrosstalk between angiogenesis and immune regulation in the tumor microenvironment
Kim, H. J., Ji, Y. R., & Lee, Y. M. (2022) · Archives of Pharmacal Research · doi:10.1007/s12272-022-01389-z · Cited by 115
“VEGF in the TME directly inhibits the trafficking, proliferation, and function of cytotoxic T lymphocytes (CTLs; Voron et al. 2015), resulting in an immunosuppressive effect.”
BackgroundHuyghe, N. D., Baldin, P., & den Eynde, M. V. (2019) · Gastroenterology report · doi:10.1093/gastro/goz061 · Cited by 114
Combination locoregional and systemic therapies in hepatocellular carcinoma
Zhong, B., Fan, W., Guan, J. J., Peng, Z., Jia, Z., Jin, H., Jin, Z.-C., Chen, J.-J., Zhu, H., & Teng, G. (2025) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00247-4 · Cited by 120
Immunotherapy for colorectal cancer: where are we heading?
Basile, D., Garattini, S. K., Bonotto, M., Ongaro, E., Casagrande, M., Cattaneo, M., Fanotto, V., De Carlo, E., Loupakis, F., Urbano, F., et al. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1315405 · Cited by 99
“Moreover, some authors observed that VEGF-A blockade could help sensitize T cells to anti-PD-1 treatment and that high VEGF-A levels may be involved in resistance to this treatment [86].”
Background
Metadata
- Authors
- Voron, T., Colussi, O., Marcheteau, E., Pernot, S., Nizard, M., Pointet, A.-L., Latreche, S., Bergaya, S., Benhamouda, N., Tanchot, C., Stockmann, C., Combe, P., Berger, A., Zinzindohoue, F., Yagita, H., Tartour, E., Taieb, J., & Terme, M.
- Affiliations
- Inserm (FR)
- Hôpital Européen Georges-Pompidou (FR)
- Service d’immunologie biologique 2 , 3 , 4 , 5
- Department of Immunology, Juntendo University School of Medicine, Tokyo 113-8421, Japan 6
- INSERM U970, Paris Cardiovascular Research Center, Université Paris-Descartes, Sorbonne Paris Cité, 75015 Paris, France 1
- ORCID
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2015-01-19
- Volume
- 212
- Issue
- 2
- Pages
- 139-148
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- PMC
- PMC4322048
- OpenAlex
- W2156906256
- Cited by
- 1,179
- References
- 32
- Citations by year
- 2026: 81 · 2025: 100 · 2024: 121 · 2023: 142 · 2022: 169 · 2021: 147 · 2020: 127 · 2019: 92 · 2018: 81 · 2017: 51 · 2016: 50 · 2015: 16
- FWCI
- 28.83
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Experimental Medicine (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Ligue Contre le Cancer
- Assistance publique-Hôpitaux de Paris
- Fonds d’Etudes et de Recherche du Corps Médical
- Japan Society for the Promotion of Science (26290059)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- VEGF-A, PD-1, CTLA-4, TIM-3, CD8+ T cell exhaustion, tumor immune evasion, tumor microenvironment, anti-angiogenic therapy, VEGFR inhibition, immune checkpoint inhibitors, cancer immunotherapy
- MeSH terms
- Animals, Disease Models, Animal, Female, Neoplasms, Protein Binding, Signal Transduction, Gene Expression Regulation, Neoplastic, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Gene Expression Profiling, Receptors, Vascular Endothelial Growth Factor, Vascular Endothelial Growth Factor A, Mice, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.